SLC5A2 and hydrops fetalis: Recent trials with SGLT2 inhibitors have also shown benefits concerning HF-related hospitalization and CV mortality in subjects admitted to the hospital due to acute decompensated HF (SOLOIST-WHF trial: sotagliflozin and EMPULSE trial: empagliflozin) [133, 134].